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Background: The global expansion of biobanks has led to a range of bioethical concerns related to consent,
privacy, control, ownership, and disclosure. As an opportunity to engage broader audiences on these concerns,
bioethicists have welcomed the commercial success of Rebecca Skloot’s 2010 bestselling book The Immortal Life of
Henrietta Lacks. To assess the impact of the book on discussion within the media and popular culture more
generally, we systematically analyzed the ethics-related themes emphasized in reviews and articles about the book,
and in interviews and profiles of Skloot.
Methods: We conducted a content analysis of a population of relevant English-language articles and transcripts
(n = 125) produced by news organizations and publications in the U.S., Canada, Great Britain/Ireland, and Australia/
New Zealand. We scored each article for the emphasis and appearance of 9 ethics-related themes. These were
informed consent, welfare of the vulnerable, compensation, scientific progress, control/access, accountability/
oversight, privacy, public education, and advocacy.
Results: The informed consent theme dominated media discussion, with almost 39.2 percent of articles/transcripts
featuring the theme as a major focus and 44.8 percent emphasizing the theme as a minor focus. Other prominent
themes and frames of reference focused on the welfare of the vulnerable (18.4 percent major emphasis; 36.0
percent minor emphasis), and donor compensation (19.2 percent major; 52.8 percent minor). Ethical themes that
comprised a second tier of prominence included those of scientific progress, control/access, and accountability/
oversight. The least prominent themes were privacy, public education, and advocacy.
Conclusions: The book has been praised as an opportunity to elevate media discussion of bioethics, but such
claims should be re-considered. The relatively narrow focus on informed consent in the media discussion generated
by Skloot’s book may limit the ability of ethicists and advocates to elevate attention to donor control,
compensation, patenting, privacy, and other ethical issues. Still, ethicists should view the book and a pending major
TV film translation as opportunities to highlight through media outreach, consultation exercises and public forums a
broader range of bioethical concerns that would otherwise be under-emphasized in news coverage. Such efforts,
however, need to be carefully planned and evaluated.* Correspondence: nisbet@american.edu
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More than $1 billion has been spent on establishing bio-
banks worldwide [1] and the sector’s commercial value
is predicted to grow to more than $2.25 billion by 2015
[2]. At least 300 million human samples are stored in
U.S. biobanks alone, and this number is estimated to be
growing by at least 20 million a year. In the United
Kingdom, a government-sponsored biobank launched in
2004 has already enrolled 500,000 donors, processing
samples from 700 to 1,000 volunteers a day [3]. Yet as
commercial repositories for tissues, fluids, genetic mater-
ial, and correlated lifestyle data, biobanks raise a range of
questions related to ethics, policy, and communication.
In a recent article at Nature Biotechnology, bioethicists
and legal scholars note that “[a]lthough informed con-
sent remains one of the most contested issues of bio-
bank policy, other legal and ethical challenges also
require careful attention” [4]. These include the protec-
tion of vulnerable subjects, the safeguarding of privacy,
the communication to donors of research results, con-
flicts over patenting, access, and the need for open sci-
ence, and the rights of donors to retain a property claim
or control over their tissues. Experts more critical of
biobank procedures and policies, such as U.S. bioethicist
Lori Andrews, have argued the need for a tissue-rights
movement in which members of the public become
“conscientious objectors in the DNA draft,” a strategy
intended to challenge status quo policy [5,6] p. 320. Ne-
gotiating all of these issues is complicated by a lack of
clear national and international oversight [4].
In this study, we examine the media discussion ge-
nerated by the 2010 best-selling popular science book
The Immortal Life of Henrietta Lacks by U.S science
writer Rebecca Skloot [5]. Many bioethicists and com-
mentators have praised the book as a leading opportu-
nity to constructively engage a broader public on the
ethical issues related to biobanks and tissue research
more generally. The book documents the story of
Henrietta Lacks, a young African-American woman who
died of cervical cancer at Baltimore, Maryland’s Johns
Hopkins Hospital in 1951. Skloot described how cells
removed from the body of the mother of five without
her permission as she lay dying were given the label
HeLa and, for a reason still unknown precisely to
scientists, became the first human cell line to survive
outside the body, contributing ultimately to vaccines,
drugs and treatments for polio, hemophilia, HIV and
several forms of cancer. Skloot weaves together three
connected narratives: the story of Henrietta’s life; the
story of how scientists used her cells to achieve extra-
ordinary medical advances; and the story of how the
Lacks family, particularly her daughter Deborah, strug-
gled to come to terms with her mother’s legacy. Running
through these stories is the history of exploitation ofAfrican-Americans for research by the medical establish-
ment in the United States.
Most biobanks today collect finite amounts of tissue,
very few of which are made into “immortal” cell lines as
was the case with HeLa. In addition, many biobanks do
not use tissues removed during medical procedures, as
was the case with Lacks. Yet the story presented by
Skloot had the potential to generate a broader discussion
in the media and among the public about the ethical
concerns related to biobanks and tissue research, a dis-
cussion that Skloot herself attempted to generate in
media interviews, in the afterward to her book, and in
prominent freelance articles.Biobanks as a communication challenge
In relation to biobanks and ethics, there are several ma-
jor communication challenges. In order to effectively
detect associations between genetic factors, environmen-
tal influences, and a specific disease, scientists require
biobanks stocked with tens of thousands of samples. As
a consequence, biobanks depend on participation from
massive numbers of donors, who consent broadly to the
use of their biological samples for a diversity of research
purposes [7]. For example, in an effort to understand
gene-environment interactions that influence disease
across the U.S. population, the National Institutes of
Health is considering a study that would involve 500,000
volunteers. Researchers would take biological samples
and track subjects across a period of years and possibly
decades. Without elevated attention and discussion of
biobanks in the U.S., participation at the scale needed
for the NIH proposed study is unlikely [8].
However, few members of the public have heard of
biobanks, even though their own samples may already
be stored or used by researchers. According to a survey
analysis conducted in 2010, two-thirds of Europeans
were unaware of biobanks, but those who had heard
about the repositories were more likely to participate as
donors and to give broad consent. The proportion of the
public prepared to participate in biobanks varied by
country and also depended in part on how much trust
citizens in different countries placed in their respective
governments. The authors of the European analysis sug-
gest that increased media attention and debate can use-
fully contribute to greater knowledge and interest in
biobanks. “Controversies don’t seem to lead people to
reject the idea of biobank research per se,” they wrote.
“Instead they facilitate the spread of information, and
improve understanding and sharing of views on what is
appropriate and acceptable use of samples.” As they
conclude: “What is needed is a dialogue with the public,
to explain the purposes of biobanks and how they ope-
rate, and to give people an opportunity to voice their
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pation” [1].
Communication matters in other ways as well. A 2008
U.S. study employing 16 focus groups comprised of 141
subjects recruited from 6 different cities concluded that
information and awareness are not only linked to a will-
ingness to participate in biobank efforts examining gene-
environment interactions, but also to a strong preference
that the public be given ongoing choices on how re-
search results could be accessed. In this case, public
awareness not only appears to create demand for greater
donor control and empowerment, but also creates ethi-
cal, logistical, and communication challenges specific
to the effective and responsible release of research re-
sults [7].
Over the past decade, science organizations and insti-
tutions have increasingly turned to consultation exerci-
ses such as public meetings to facilitate public learning
and dialogue about complex policy questions such as
those posed by biobanks [9]. One notable study orga-
nized town meetings in 5 U.S. cities, consulting the pub-
lic on biobank-related issues such as the protection of
privacy, the sharing of research results, and the profits
made by biotechnology companies [10]. Yet, as many
previous studies suggest, even with increased investment
in consultation exercises, the news and entertainment
media remain the main forum through which the broa-
dest and most diverse segments of the public are likely
to learn about and form at least tentative opinions about
complex biomedical topics. In this sense, consultation
exercises provide the opportunity and means by which
motivated members of the public can learn, discuss, and
sort through ethical and legal issues related to biobanks.
For much of the rest of the public, the news media and
popular culture serve a surveillance function, calling their
attention to an issue like tissue research, and in the pro-
cess, defining its’ significance [11].
The impact of a popular science best-seller
A major critical and commercial success, The Immortal
Life of Henrietta Lacks appeared on the New York Times
hardcover bestseller list for more than 11 months, and
had sold, by 2011, more than 1.25 million copies in the
U.S. alone. As of 5 August 2012, the book had been on
the New York Times paperback non-fiction bestseller list
for more than 18 months. The book is under develop-
ment as an HBO film by producer Oprah Winfrey, and a
young adult edition of the book is planned for readers
ages 10 to 14 [12].
The New York Times wrote that the book is “from first
page to last, a meditation on medical ethics – on the no-
tion of informed consent, and on the issue of who owns
human cells” [13]. The Washington Post said the book
was an investigation of “a social wrong committed bythe medical establishment” [14]. Britain’s The Indepen-
dent on Sunday described the book as “a case study of
race and medical ethics, of the problems that plague
black society. . .” [15]. Novelist Hilary Mantel, writing in
The Guardian, noted: “The dark, inhuman face of un-
policed science shows itself throughout this story, side
by side with the bright face of discovery and humanitar-
ian advance” [16]. The U.S National Academies awarded
the book a 2011 Keck Prize for science communication,
and cited Skloot’s work as: “A compelling and graceful
use of narrative that illuminates the human and ethical
issues of scientific research and medical advances” [17].
Best-selling science books do not merely engage and
educate readers, but they also make policy-related argu-
ments, shape news coverage, and become a topic of wi-
der cultural discussion [18]. These books make complex
scientific and ethical topics meaningful for audiences by
presenting them in terms of specific themes and nar-
ratives. As organizing devices, narratives provide a spe-
cific temporal order of events, arranged in a dramatic
plot, creating a rhetorical sequence which reaches a cli-
max that leads to a resolution that helps audiences un-
derstand the moral lessons and conclusions to be taken
from the story [19]. In other words, narratives make
issues concrete and coherent, meaningful and memo-
rable, emphasizing certain ethical themes and moral
judgments over others [20]. Yet, the choice by jour-
nalists like Skloot to focus on some ethical conside-
rations while paying less attention to others can have
important implications for how readers understand a
complex topic like tissue donation and research [21].
In interviews related to her book, Skloot provided
insight on the narrative choices and specific themes that
she used to structure her book. She described, for ex-
ample, the importance of telling a personal story. As
Skloot told Niemen Reports: “Among other things, my
book is the history of tissue culture and the evolution of
bioethics told through the story of a family.” The book’s
narrative arc “was really the story of Deborah [Lacks]:
her struggle to learn who her mother was, to come to
terms with the cells,” said Skloot [22]. The commercial
success and wide public interest in the book has been
attributed strongly to the foregrounding of the Lacks’
story. As a review in The Sunday Times (UK) by Bryan
Appleyard, noted: “The primary narrative concerns race,
poverty – financial and educational – and the abyss that
divides the scientific understanding of the human body
from the people’s. It is her adoption of this primary nar-
rative that makes Rebecca Skloot’s book such a gripping
read” [23].
Yet by strongly foregrounding the individual case of
Lacks, Skloot risked not only obscuring other important
ethical issues but also limiting reader consideration of
deeper questions related to biomedical research and the
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ample, Skloot noted that she intended the book to serve
as a warning about the dangers of treating life instru-
mentally and of the need to think broadly about history,
policy arrangements, and governance. As she told the
Wisconsin State Journal: “It’s really important for scien-
tists in general to think about the fact that there are
human beings behind every biological sample that we
use in a laboratory . . . Also, it's a story about how scien-
tific progress happens faster than the regulations that
govern it” [24]. She also told The Calgary Herald that
the book relates to several current health policy issues,
including access to health care for minorities, science
education, and the importance of scientists communicat-
ing with non-specialists [25].
Skloot attempted to balance the personalized focus of
the book’s main narrative with a 13-page afterward that
reads like a more broadly contextualized policy brief. Yet
even in this case, Skloot makes specific choices about
how to define the relevant ethical issues involved in tis-
sue donation and research. As she writes:
There are, essentially, two issues to deal with: consent
and money. For most people, knowing if and how
their tissues are being used in research is a far bigger
issue than profiting from them. Yet when this book
went to press, storing blood and tissues for research
did not legally require informed consent, because the
law governing such things doesn’t generally apply to
tissue research [5] p. 317.
Her afterward and the specific themes emphasized
mirror closely a 7,500 word feature that Skloot published
at the New York Times Magazine in 2006. The feature,
subtitled “The Tissue Industrial Complex,” is noteworthy
for not mentioning the Henrietta Lacks case, but instead
foregrounding at the opening of the article the growth in
tissue storage and a corresponding lack of clear regula-
tory and governing arrangements. Yet in defining more
broadly the problem, Lacks again leads readers back to
informed consent as the solution. The apparent implica-
tion is that as long as informed consent is satisfied, then
other questions such as donor control become secondary.
Consider a leading example from the article, in which she
discusses two major historic cases:
“The difference between Ted Slavin and John Moore
wasn’t that Slavin owned his tissues and Moore didn’t
. . . The difference was information. Someone told
Slavin that his tissues were special and that scientists
might want them. So he was able to control his
tissues by establishing his terms before anything left
his body. In other words, he was informed, and he
gave consent. In the end, the question isn’t whetherpeople have the ability to control their tissues; it is
how much science should be obligated (ethically and
legally) to put them in a position to do so” [26].
To date, even among academics, there has been li-
mited in-depth analysis of the book’s substantive treat-
ment of the ethical and policy questions related to tissue
research, donation, and biobanks. An exception is an 18
June 2012 review essay that appeared at the conservative
journal The New Atlantis. Writer Ari N. Schulman cri-
tiques efforts to allow the market to govern decisions
about research, and warns that Skloot’s emphasis may
lead others to view informed consent as a “panacea” for
a range of unaddressed ethical problems [27].
In addition, there has yet to be a systematic analysis of
how Skloot’s book has been discussed in media reviews,
coverage, and commentary. Given the importance of the
media to how the broader public understands the nature
of bioethics and biobanks specifically, along with the
special role that best-selling science books can play in
reaching wider audiences, the purpose of this study
is therefore to systematically evaluate the ethical the-
mes emphasized in the media coverage generated by
the book.
Methods
In order to determine relevant reviews, news stories,
features, commentaries, profiles, and interviews genera-
ted by the publication, promotion, and success of Re-
becca Skloot’s The Immortal Life of Henrietta Lacks, we
searched the LexisNexis and Factiva databases between
January 1, 2009 and June 15, 2012, for English-language
articles and transcripts containing in the full text the key
words “Rebecca Skloot” or “Henrietta Lacks.” The time
period searched covers both advance promotion, the re-
lease of the hardcover edition, the release of the paper-
back edition, and the related promotional efforts by
Skloot and her publisher. We individually reviewed each
of the initially identified articles and transcripts, discar-
ding duplicates or non-relevant articles. We then com-
pared our remaining articles and transcripts to those
listed by her publisher at Rebecca Skloot’s promo-
tional Web site, retrieving via the Web relevant arti-
cles or transcripts that were not included in the culled
population.
This process resulted in a final population of 125 ar-
ticles and transcripts. These included 52 book reviews,
43 news stories or features, 22 profiles or interviews of
Skloot, and 8 editorials, columns, op-eds, or letters-to
-the-editor. Of the print and Web articles, 88 appeared
at newspapers, 9 at public affairs magazines such as The
Economist or Slate, 7 at trade journals such as Library
Journal or Publishers Weekly, 6 at science or medical
journals such as Nature or The Lancet, 5 at news wire
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science magazines such as The New Scientist, and 1 at
the magazine Entertainment Weekly. Among the pro-
grams retrieved, 4 were transcripts of interviews with
National Public Radio affiliated programs such Science
Friday or Fresh Air, and 3 were interviews with TV net-
work programs at ABC News and PBS.
To assess the ethical themes featured in the articles,
we developed a coding typology (see Table 1) by first
reviewing key texts or articles that identify the major
principles of bioethics [28,29] as well as recent journal
articles or reports specific to the ethical and policy im-
plications of biobanks and tissue research [1,4]. We
further refined the typology by then comparing our pre-
liminary categories to the themes emphasized by Skloot
in her book and by similar works intended for a popular
audience such as Lori Andrews’ and Dorothy Nelkin’s
Body Bazaar: The Market for Human Tissue [6]. We
then evaluated the validity of the typology in a pilot
study that informally reviewed the population of 125
articles and transcripts.
Based on a previously developed coding methodolo-
gy for analyzing coverage of biotechnology debates, for
each article or transcript, we scored each theme as “not
present = 0,” “present = 1,” or “outstanding focus/appea-
ring in the lede/headline” of the article/transcript = 2
[30,31]. At the start of our coding process, we tested our
inter-coder agreement on a sample of 40 of the articles
and transcripts. Based on careful review and pilot testing,Table 1 Typology of ethical themes
Theme Description
Welfare of Vulnerable, Sanctity of Person
(Welfare)
Focus on possible mistreatmen
groups, veterans or soldiers, ch
product, commodity, subject ra
Informed Consent (Consent) Focus on notification/education
different consent models such
Compensation, Benefit, Profit Sharing
(Compensation)
Focus on benefits to patient/do
fairness and balance between f
Privacy, Discrimination, Sharing Results
(Privacy)
Focus on protecting privacy an
patient/donor should be notifie
contacted; possible harm or be
Patient Control, Data Access, Patenting
(Control)
Focus on patient/donor’s ability
specimen from biobank or data
patenting of specific therapies
Accountability, Regulation, Oversight
(Accountability/Oversight)
Focus on nature or absence of
of tissue/DNA storage and use;
legal action.
Scientific, Societal Progress (Progress) Focus on need for tissue/DNA
benefits of progress outweighin
Public Education, Consultation (Education) Focus on need for government
focus on need for direct public
Includes general reference to p
Advocacy, Activism (Advocacy) Focus on call for action for “tiss
social groups to challenge the
or to shift away from culture ofour eventual agreement on scoring decisions across the-
mes was 80 percent or higher for the 40 articles scored in
the sample. After establishing reliability, we then moved
forward to individually code the rest of the articles and
transcripts in the population.
Results
As Table 2 indicates, 39.2 percent of articles and trans-
cripts featured discussion of informed consent as the ma-
jor ethical issue relevant to the Lacks case, or tissue
research more generally, or both. Another 44.8 percent
emphasized the theme as a secondary concern. In total,
84 percent of articles or transcripts mentioned informed
consent. As an example, consider this lede from a review
at the liberal Mother Jones magazine: “When Henrietta
Lacks – a poor, African American tobacco farmer from
Virginia – checked into Johns Hopkins Hospital with
cervical cancer in 1951, she had no idea that tissue
removed from her body without her consent would be-
come one of the most important resources in medical
history” [32].
Though the theme of informed consent dominated po-
pular discussion of the book, also prominent was an
emphasis on the welfare of the vulnerable (18.4 percent
major emphasis; 36.0 percent minor emphasis) and com-
pensation (19.2 percent major; 52.8 percent minor). In
total, 54.4 percent of the articles or transcripts analy-
zed mentioned ethical considerations related to wel-
fare and 72 percent mentioned considerations relatedt, exploitation of African Americans, other minority groups; low-income
ildren, elderly, sick, and/or concerns over defining the body as an object,
ther than a person.
of patient/donor. Discussion of lack of consent, or merits/weaknesses of
as specific consent, broad consent, or presumed/opt-out consent.
nor including treatment, pay, or profit sharing; includes discussion of
inancial benefits to patient and profits made by scientists and industry.
d/or use of information to discriminate, and/or conditions under which
d of research result; ability of patient to express consent/desire to be
nefit to patient or donor.
to control research applications or uses; i.e. ability to withdraw
base; and/or researcher access and sharing of data; and/or discussion of
and diagnostic tools.
regulatory rules, oversight of public and private biobanks, management
and/or ability of patient/donor or third parties to seek regulatory or
donations and banking for scientific and social progress; emphasis on
g concerns over informed consent and other possible ethical issues.
, experts, and institutions to educate the public about issues and/or
consultation and public/stakeholder involvement in decision-making.
ublic opinion or beliefs.
ue rights movement,” and direct advocacy on the part of public and
status quo and to seek policies more in line with the public interest and/
commercialization etc.
Table 2 Percentage of articles featuring major/minor
emphasis on ethical theme
Theme Consent Welfare Compensation Progress Control
Major
% 39.2 18.4 19.2 8.0 4.8
N 49 23 24 10 6
Minor
% 44.8 36.0 52.8 26.4 18.4
N 56 45 66 33 23
Absent
% 16.0 45.6 28.0 65.6 76.8
N 20 57 35 82 96
Theme Accountability Privacy Education Advocacy
Major
% – .08 1.6 0.8
N – 1 2 1
Minor
% 26.4 12.8 6.4 4.0
N 33 16 8 5
Absent
% 73.6 86.4 92.0 95.2
N 92 108 115 119
Note: Analysis based on coding of population of 125 articles. Each theme or
frame of reference was coded as “not present = 0,” “present = 1,” or
“outstanding focus/appearing in the lede/headline” of the article/transcript = 2.
Analysis of population of relevant articles, so all differences are significant.
Some cells may not total 100 due to rounding.
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many articles/transcripts alluded to the unethical treat-
ment of blacks historically by the medical establishment
in the U.S. Specific to compensation, many reviewers or
journalists noted - as Skloot does - the contrast between
the profits generated by HeLa cells, and Lacks’ family in-
ability to afford health insurance.
Ethical themes that comprised a second tier of prom-
inence included scientific progress, patient control, and
accountability/oversight. Thirty-four percent of articles
and transcripts emphasized scientific progress, 23.2 per-
cent emphasized control, and 26.4 percent emphasized
accountability, though few featured these three themes
as major considerations.
An example of the argument that scientific progress
should be given greater weight than other ethical conside-
rations appears in a news story run by the trade publica-
tion Internal Medicine News. In this case, a scientist is
quoted as expressing concern over the attention that the
book has generated: “Rebecca Skloot’s book on Henrietta
Lacks ‘has raised sensitivity’ for many people about the
potential ethical and confidentiality dangers of biomedical
research ‘without a counterbalancing, responsible story
being told about the benefits’ of this research. . .’” [33].In emphasizing the theme of control, a review at the
Winnipeg Free Press noted: “The courts have decided
that once a bit of tissue is removed from our bodies, we
lose all ownership rights and are not entitled to share in
any profits derived. Even our own genes have been
patented for private gain, preventing the development of
cheaper and more effective methods to diagnose and
treat disease as breast cancer" [34].
The theme of accountability is emphasized in an inter-
view with Skloot published by the Atlanta Journal Consti-
tution. When asked if an individual’s tissue today could be
used without consent, Skloot replies: “There are certain
laws that say you have to be informed when scientists do
certain things. What happened with Henrietta’s family, a
scientist coming to them just to do research, they would
have to have permission for that. But everything else is
pretty loose.” [emphasis added] [35].
Finally, far less prominent themes included privacy,
public education, or advocacy with fewer than 15 per-
cent of articles mentioning these important ethical con-
siderations and very rarely as major points of emphasis.
The theme of privacy appears, for example, in a report
on the PBS program Religion & Ethics Newsweekly
which focused on the issue of tissue donation, quoting
bioethicist Jonathon Moreno: “If you take some of my
tissues, my cells, and do genetic analysis, you’re learning
not just about me, but in some measure, at least, you’re
learning about my relatives. So we have to be very sensi-
tive to the prospects of stigmatization” [36].
Education was addressed, for example, in a news story
run by Reuters, though in cautionary terms: “As it is,
Skloot said scientists fear logistical headaches if they
start relinquishing control and giving out a lot of infor-
mation to the general public. Patients may veto research
projects involving their cells due to ethical qualms, for
instance, or may demand revenues” [37]. The theme of
advocacy and activism, meanwhile, is used in the closing
paragraph of a review of the book in the New York
Times: “The notion of ‘tissue rights’ has inspired a new
category of activists. The question that comes up repeat-
edly is, if scientists or companies can commercialize a
patient’s cells or tissues, doesn’t that patient, as provider
of the raw material, deserve a say about it and maybe a
share of any profits that result? Few people these days
may be willing to take no for an answer” [38].
In Table 3, we examined the correlations among
themes, an indicator of how themes might have been
packaged together in discussion to offer a diagnostic
(i.e. problem definition) and prescriptive (i.e. problem
solution) account of the Lacks case or tissue research
more generally. In this case, two distinct groupings of
ethical themes appeared across articles. First, most
prominently, discussion of consent, welfare, and com-
pensation often appeared together in the same article,
Table 3 Correlations among ethical themes
(1) (2) (3) (4) (5) (6) (7) (8) (9)
Cons Welf Comp Prog Cont Acct Priv Edu Adv
(1) Consent 1.00
(2) Welfare .26** 1.00
(3) Compensation .26** .15 1.00
(4) Progress −.01 .02 .11 1.0
(5) Control .19* .20* .05 .16# 1.00
(6) Accountability .16# .00 .09 .14 .27** 1.00
(7) Privacy .11 .13 -.12 .06 .28** .24** 1.00
(8) Education .05 -.09 -.01 .16# .26** .36** .31** 1.00
(9) Advocacy .00 -.02 .14 .15 .23** .29** -.09** .21* 1.00
Note: Analysis based on coding of population of 125 articles. Each theme or frame of reference was coded as “not present = 0,” “present = 1,” or “outstanding
focus/appearing in the lede/headline” of the article/transcript = 2. For analysis of correlations among themes, “outstanding focus/appearing in lede/headline” and
“present categories” were combined, leaving a dichotomous measure where “1 = theme present” and “0 = theme not present”.
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Similarly, a focus on welfare and control also tended to ap-
pear together as themes in articles. This suggests that
when describing the risks from biomedical research posed
to vulnerable populations and individuals, that the themes
of consent, compensation, and control tended to be dis-
cussed as remedies or courses of action.
Second, though discussed much less frequently, an al-
ternative diagnostic and prescriptive framing of tissue
donation and research also appeared in articles. Specific-
ally, accountability, education, and advocacy all correlate
significantly and in the positive direction. Similarly, priv-
acy correlates with accountability and education, though
not with advocacy. This suggests that when issues rela-
ted to accountability/oversight or privacy were raised as
ethical concerns, the need for either public education or
advocacy, or both, were also likely offered as solutions
or courses of action.
Finally, we examined differences in the prominence of
ethical themes by article/transcript type. Reviews (28.8%),
stories/features (12.5%), and opinion articles (14%) were
more likely than profiles/interviews (4.5%) to feature a
major/lede focus on the welfare of the vulnerable as an
ethical theme. Opinion articles (37.5%) were more likely
than other article types to feature a major/lede focus on
considerations of control, an ethical dimension that was
otherwise rarely emphasized.
Conclusion
Our analysis indicates that media reviews, profiles, and
stories reflected the major ethical themes emphasized by
Skloot in her book and publicity efforts. These included
an overwhelming focus on issues related to informed
consent, the welfare of the vulnerable, the treatment of
individuals as people rather than mere subjects, and
considerations of compensation and profit sharing. Less
frequently emphasized themes included discussion ofthe conditions under which the need for scientific pro-
gress should outweigh other ethical concerns, the con-
trol that donors might have over their specimens, the
balance between patenting and access to research, and
accountability or oversight relative to current policies
and procedures. Rarely mentioned or emphasized were
considerations related to donor privacy and access to re-
search results, to public education, or to the role of ad-
vocacy and activism.
Relative to understanding the direct impact of Skloot’s
book on public judgments, our findings should be
interpreted cautiously. Our study identified the range of
arguments and themes that were most readily available
via the media for the public to draw upon in forming
opinions and making decisions. These findings, however,
should be paired with direct audience research
employing surveys, focus groups, in depth interviews
and other methods. In coding the results of open-ended
surveys, however, the typology of themes that we
developed can be usefully applied. The coding scheme
can also be used in future research related to media
coverage and policy discourse specific to biobanks, in-
cluding the type of discourse that takes place at public
meetings and events.
Given the nature of our study, it is also not possible to
say with confidence if Skloot’s book was the principal
driver of the focus on informed consent in reviews, pro-
files, news stories, and opinion articles. Journalists and
reviewers are not only influenced by the content of the
book (and related publicity materials), but also by broa-
der cultural and political discourses about biomedical
research. Yet regardless of the factors ultimately respon-
sible for the strong emphasis on informed consent, the
narrow focus may in fact limit the ability of ethicists and
advocates to elevate attention to donor control, com-
pensation, patenting, privacy, and other ethical issues.
In this regard, even though some scientists have voiced
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arrangements specific to tissue donation and research,
our findings suggest that the book may in fact serve to
reinforce them.
There are other important implications for the journa-
listic treatment and communication of bioethics to the
broader public. First, in contrast to the emphasis that
has been placed on public education to ensure broader
participation and enrollment in biobanks, media discus-
sion of the book involves little to no emphasis on a role
for the public. This may be in line with a view of the
book by journalists and reviewers as mainly a cultural
commodity and entertainment product to be reviewed,
rather than an important opportunity to discuss biome-
dicine more broadly. Skloot herself has been acclaimed
as a model of marketing and self-promotion, and media
discourse for the most part characterizes the public as
spectators and consumers rather than as active parti-
cipants in an emerging policy debate.
Similarly, because discussion of the book occurred lar-
gely in reviews, author interviews and profiles, the book
has yet to serve as a catalyst for in depth news coverage
of biobanks and related issues. Extended public radio
interviews, however, did allow for richer discussions of
bioethics than were featured in the arts and culture sec-
tion of other news organizations. The greater attention
in opinion articles to ethical themes related to control,
access, and patenting suggests that opinion writers and
editors more so than other journalists viewed it as their
role to use Skloot’s book as an opportunity to raise a
broader set of ethical questions. These types of discussions
have the potential to contribute to public understanding
of the complex ethical issues related to biobanking, espe-
cially as there is a lack of consensus on these questions,
including the meaning of consent, among both the public
and experts [39].
Yet despite this potential, the book has yet to prompt
journalistic investigations of informed consent policies
and practices, has resulted in very few backgrounders on
the ethical and policy issues involved, and has generated
little attention to the global growth of biobanks specific-
ally. The best-seller has been hailed as an opportunity to
elevate discussion of bioethics in the media more gener-
ally, but the failure so far to catalyze these types of sto-
ries – along with the narrow framing of ethical issues
featured in coverage of the book – suggest that such
claims should be re-considered.
Finally, the success of the book should demonstrate to
bioethicists and scientists that there is an intense public
appetite for compelling narratives about advances in
medical research and the ethical issues involved. As has
been done in some university reading initiatives, the
book’s popularity can serve as the starting point for com-
munity dialogue and discussion of a broader and morediverse set of ethical themes and frames of reference. With
a major HBO film expected, the film may further widen
the scope of public interest and the opportunity for
engagement. Such efforts, however, need to be carefully
planned and evaluated. Ethicists, scientists, and others
should view subsequent media manifestations of the book
as opportunities to highlight bioethical issues that would
otherwise be under-emphasized in news coverage, com-
mentaries, and reviews.
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